These results imply that the leptin/LepRb signaling pathway is the direct inhibitory target of PF, resulting in the amelioration of PI-IBS symptoms, including excessive fibrotic remodeling in the submucosa and smooth muscle, chronic mucosal injury, reduced intestinal function, and depression- and anxiety-like behaviors. The gene discussed is LEP; the disease is irritable bowel syndrome.